Posts by Noëlle Aubert

GeNeuro received CHF 6.7 million in funding for the development of temelimab against Long-COVID   GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases based in Geneva (Switzerland), with final Phase II results in multiple sclerosis expected in March 2022, announced that its development in Long-COVID is one of the four projects selected…

CHUV performed the world’s first hybrid robotic general surgery   Distalmotion & CHUV announced the successful start to a case series using Distalmotion’s surgical robot, Dexter. Prof. Dieter Hahnloser, PD Dr. Fabian Grass and their team at the CHUV were able to carry out the world’s first hybrid robotic colorectal procedure without complications. Said first procedure…

First patient enrollment   EBAMed announced first patient enrolled in prospective imaging study with ultrasound guidance prototype in ventricular tachycardia patients The first patient was enrolled at the Policlinico San Matteo, Pavia (Italy). This important company milestone was reached according to development schedule. The main objectives of the study are to collect cardiac ultrasound data…

Closing of $234 mio. Initial Public Offering & $20 mio. Private Placement   SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced the closing of its initial public offering of 13’000’000 ordinary shares at a price of $18 per share. The gross proceeds…

Interview with Andreas Schläpfer, CEO & cofounder   AC BioScience, the Vaud based company is a pioneer in the development of a novel treatment in immuno-oncology that will enhance patients immune capabilities and help them fight off cancer.    How does your company fight cancer? AC BioScience is deeply committed to fighting cancer and improving…

Scientists at EPFL (Polymers Laboratory) and the University of Warwick have used a virus to identify a peptide that can serve the same function as antifreeze proteins. By preventing ice formation, the compound could play a key role in preserving cells and organ transplants and in food conservation.   Some organisms have developed special “antifreeze”…

Tissue grows back once the implant is gone   EPFL engineers have developed a neural interface that disappears harmlessly in the body after several months and allows natural tissue to grow back. What’s more, it can be implanted in a patient’s blood vessel rather than inside the brain, thereby avoiding the need for invasive surgery.…

Digital support to Gait Up    CSEM posted a solid financial performance in 2020 and made further progress on important technological breakthroughs despite the economic and social impact of the pandemic. CSEM’s staff worked hard throughout the year, fulfilling the Center’s mission: providing industry with cutting-edge R&D. The full-year results are encouraging, and the Center is…

CHF 50 million for diabetes ventures Launch of the first venture fund dedicated to diabetes technology, through a collaboration between the Swiss Startup Group, the Diabetes Center Berne and Simon Michel. The Swiss Diabetes Venture Fund (SDVF) will invest up to CHF 50 million over the next 5 years, with a target portfolio size of…